Table 2. In vitro ABT-199 EC50 fold-shift enhancement by siRNA.
| Cell line |
siRNA |
|
|---|---|---|
| BCL-XL | MCL-1 | |
| SET-2 | 1.2±0.1 (P=0.032) | 1.5±0.3 (P=0.049) |
| TF-1 | 1.6±0.2 (P=0.0073) | 2.3±1.0 (P=0.076) |
| THP-1 | 4.2±2.8 (P=0.11) | 8.5±2.4 (P=0.0079) |
| OCI-AML3 | 2.4±1.0 (P=0.067) | 6.9±0.9 (P=0.0084) |
BCL-XL and MCL-1 siRNA knockdown combined with ABT-199 drug-dose-response in myeloid cells in vitro. Cell lines are listed in the left-most column. The BCL-2 family member silenced by siRNA before assessing ABT-199 drug-dose-response is shown as the heading for each column. ABT-199 EC50 fold-shifts, determined relative to non-silencing siRNA, are listed with P-values associated with EC50 fold-shift measurements averaged for four different siRNA sequences against each BCL-2 family member.